{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Sharma M"],"funding":["National Institute of Pharmaceutical Education and Research, Ahmedabad","Department of Chemicals and Petrochemicals, Ministry of Chemicals and Fertilizers","European Commission","Department of Biotechnology, Ministry of Science and Technology, India"],"pagination":["40-51"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9841796"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["6(1)"],"pubmed_abstract":["Parkinson's disease (PD) is a progressive neurodegenerative disease with no permanent cure affecting around 1% of the population over 65. There is an urgency to search for a disease-modifying agent with fewer untoward effects. PD pathology involves the accumulation of toxic alpha-synuclein (α-syn) and neuronal inflammation leading to the degeneration of dopaminergic (DAergic) neurons. Swertiamarin (SWE), a well-studied natural product, possesses a strong anti-inflammatory effect. It is a secoiridoid glycoside isolated from <i>Enicostemma littorale</i> Blume. SWE showed a reversal effect on the α-syn accumulation in the 6-hydroxydopamine (6-OHDA)-induced <i>Caenorhabditis elegans</i> model of PD. However, there are no reports in the literature citing the effect of SWE as a neuroprotective a"],"journal":["ACS pharmacology & translational science"],"pubmed_title":["Neuroprotective Effect of Swertiamarin in a Rotenone Model of Parkinson's Disease: Role of Neuroinflammation and Alpha-Synuclein Accumulation."],"pmcid":["PMC9841796"],"funding_grant_id":["LX22NPO5107"],"pubmed_authors":["Sharma N","Kate AS","Juvvalapalli SS","Goswami A","Khairnar A","Malim FM","Chatterjee S","Sharma M"],"additional_accession":[]},"is_claimable":false,"name":"Neuroprotective Effect of Swertiamarin in a Rotenone Model of Parkinson's Disease: Role of Neuroinflammation and Alpha-Synuclein Accumulation.","description":"Parkinson's disease (PD) is a progressive neurodegenerative disease with no permanent cure affecting around 1% of the population over 65. There is an urgency to search for a disease-modifying agent with fewer untoward effects. PD pathology involves the accumulation of toxic alpha-synuclein (α-syn) and neuronal inflammation leading to the degeneration of dopaminergic (DAergic) neurons. Swertiamarin (SWE), a well-studied natural product, possesses a strong anti-inflammatory effect. It is a secoiridoid glycoside isolated from <i>Enicostemma littorale</i> Blume. SWE showed a reversal effect on the α-syn accumulation in the 6-hydroxydopamine (6-OHDA)-induced <i>Caenorhabditis elegans</i> model of PD. However, there are no reports in the literature citing the effect of SWE as a neuroprotective a","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Jan","modification":"2025-04-05T16:14:08.838Z","creation":"2025-04-05T16:14:08.838Z"},"accession":"S-EPMC9841796","cross_references":{"pubmed":["36654754"],"doi":["10.1021/acsptsci.2c00120"]}}